Sarah Phillips

Associate, Silicon Valley

Biography

Overview

Sarah Phillips is an associate in the Mergers and Acquisitions Practice Group, and is resident in White & Case's Silicon Valley office.

Ms. Phillips advises corporate clients in connection with domestic and global mergers and acquisitions, venture capital and private equity transactions, divestitures, restructurings, and joint ventures in a broad range of industries, including healthcare, transportation and banking, but with a particular focus on the technology industry. Such technologies have included semiconductors, cloud computing and software, autonomous vehicles and blockchain.

Ms. Phillips also provides general corporate and corporate governance advice.

Representative matters include:

  • Representation of Flying Eagle Acquisition Corp. (NYSE: FEAC), a SPAC, in its US$4.3 billion business combination with Skillz Inc., a mobile-gaming company based in California.
  • Representation of Ascendant Digital Acquisition Corp. (NYSE: ACND), a SPAC, in its US$3 billion business combination with Beacon Street Group, LLC, a leading multi-brand digital subscription service platform that provides premium financial research, software, education and tools for self-directed investors.
  • Representation of CM Life Sciences II (NASDAQ: CMII), a SPAC sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, in its US$1.23 billion business combination with SomaLogic, Inc., a protein biomarker discovery and clinical diagnostics company.
  • Representation of FS Development Corp. II (NASDAQ: FSII), a SPAC, in its US$276.2 million business combination with Pardes Biosciences, Inc., an early stage biopharmaceutical company developing a potential direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections.
  • Representation of QH Oil Investments LP, an affiliate of Qatar Investment Authority, on its investment in the US$230 million Series B fundraising of Tessera Therapeutics, Inc., an early-stage life sciences company founded by Flagship Pioneering that is pioneering Gene Writing, which was co-led by Alaska Permanent Fund Corporation, Altitude Life Science Ventures, and SoftBank Vision Fund 2.
  • Representation of CVC Capital Partners in its acquisition of a majority stake in MedRisk, a leading provider of managed physical medicine services for the workers' compensation industry in the United States.
     
Bars and Courts
California State Bar
Education
JD
University of Pennsylvania Law School
BA
University of California, Berkeley
Languages
English

Experience

Representation of Flying Eagle Acquisition Corp. (NYSE: FEAC), a SPAC, in its US$4.3 billion business combination with Skillz Inc., a mobile-gaming company based in California.

Representation of CVC Capital Partners in:

  • a consortium of investors in the US$3.5 billion investment for a 22.55% stake in Authentic Brands Group LLC, a brand management company and owner of a portfolio of brand name companies.
  • its acquisition of a majority stake in MedRisk, a leading provider of managed physical medicine services for the workers' compensation industry in the US.

Representation of Ascendant Digital Acquisition Corp. (NYSE: ACND), a SPAC, in its US$3 billion business combination with Beacon Street Group, LLC, a leading multi-brand digital subscription service platform that provides premium financial research, software, education and tools for self-directed investors.

Representation of CM Life Sciences II (NASDAQ: CMII), a SPAC sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP, in its US$1.23 billion business combination with SomaLogic, Inc., a protein biomarker discovery and clinical diagnostics company.

Representation of DFP Healthcare Acquisitions Corp. (NASDAQ: DFPH, DFPHW), a SPAC, in its US$842 million business combination with The Oncology Institute, a US market-leader in value-based oncology care.

Representation of Deerfield Healthcare Technology Acquisitions Corp. (NASDAQ: DFHT), a SPAC, in its US$614 million business combination with CareMax Medical Group, L.L.C. and IMC Medical Group Holdings LLC, creating a technology-enabled care platform providing value-based care and chronic disease management to seniors.

Representation of FS Development Corp. II (NASDAQ: FSII), a SPAC, in its US$276.2 million business combination with Pardes Biosciences, Inc., an early stage biopharmaceutical company developing a potential direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections.

Representation of Biosight Ltd., a privately held pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, in its reverse merger transaction with Advaxis, Inc. (NASDAQ: ADXS), pursuant to which the shareholders of Biosight will become the majority holders of the combined company immediately following completion of the transaction.

Representation of QH Oil Investments LP, an affiliate of Qatar Investment Authority, on its investment in the US$230 million Series B fundraising of Tessera Therapeutics, Inc., an early-stage life sciences company founded by Flagship Pioneering that is pioneering Gene Writing, which was co-led by Alaska Permanent Fund Corporation, Altitude Life Science Ventures, and SoftBank Vision Fund 2.